Brief: Vaccinex Reports Positive Effect Of Pepinemab Treatment On New Biomarker Of Brain Inflammation In Neurodegenerative Diseases
26/10/2023 15:09
Oct 26 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX REPORTS POSITIVE EFFECT OF PEPINEMAB TREATMENT ON
NEW
BIOMARKER OF BRAIN INFLAMMATION IN NEURODEGENERATIVE DISEASES
Source text for Eikon: ID:nGNXb9lrFl
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease